Effects of delta-9-tetrahydrocannabinol and (R)-methanandamide on open- field behavior in rats

Behavioural Pharmacology

Volumn 9, Issue 2, 1998, Pages 169-174

  Jarbe T U C ^a   Sheppard, R ^a   Lamb, R J ^a   Makriyannis, A ^b   Lin, S ^b   Goutopoulos, A ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

(R) methanenandamide; Cannabinoid; Cannabinoid antagonist; Delta 9 tetrahydrocannabinol; Open field; Rat; SR 141716

Indexed keywords

ANANDAMIDE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DEFECATION; DRUG EFFECT; DRUG POTENCY; GROOMING; MALE; MICTURITION; MOBILIZATION; NONHUMAN; OPEN FIELD BEHAVIOR; RAT; REARING;

ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACIDS; DEFECATION; GROOMING; MALE; PSYCHOMOTOR PERFORMANCE; PSYCHOTROPIC DRUGS; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROCANNABINOL; URINATION;

EID: 0031902366     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A (1994). (R)-methanadamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem 37:1889-1893.
2. Berdyshev EV, Bichot E, Lagente V (1996). Anandamide - a new look on fatty acid ethanolamides. J Lipid Mediators Cell Signal 15:9-67.
3. Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34:605-613.
4. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G et al. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
5. Hanus L, Gopher A, Almog S, Mechoulam R (1993). Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem 36:3032-3034.
6. Howlett AC (1995). Pharmacology of cannabinoid receptors. Ann Rev Pharmacol Toxicol 35:607-634.
7. Järbe TUC (1978). Delta-9-tetrahydrocannabinol: tolerance after noncontingent exposure in rats. Arch Int Pharmacodyn Ther 231:49-56.
8. Järbe TUC, Henriksson BG (1973). Open-field behavior and acquisition of discriminative response control in delta-9-THC tolerant rats. Experientia 29:1251-1253.
9. Järbe TUC, Hiltunen AJ (1987). Cannabimimetic activity of cannabinol in rats and pigeons. Neuropharmacology 26:219-228.
10. Kirk RE (1968). Experimental design: procedures for the behavioral sciences. Belmont: Brooks/Cole; 1968.
11. Mechoulam R, Hanus L, Martin BR (1994). Search for endogenous ligands of the cannabinoid receptor. Biochem Pharmacol 48:1537-1544.
12. Munro S, Thomas KL, Abu-Shaar M (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365:61-65.
13. Pertwee RG, Coutts A, Griffin G, Fernando SR, McCallion D, Stevenson LA (1996). The presence of cannabinoid CB1 receptors of prejunctional neurones of certain isolated tissue preparations: a brief review. Med Sci Monitor 2:840-848.
14. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C et al. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Letters 350:240-244.
15. Romero J, Garcia-Palomero E, Lin Sy, Ramos JA, Makriyannis A, Fernandez-Ruiz JJ (1996). Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand. Life Sci 58:1249-1257.
16. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R (1997). Structural requirements for binding of anandamide-type compounds to the brain receptor. J Med Chem 40:659-667.
17. Sjöden PO, Järbe TUC, Henriksson BG (1973). Effects of long-term administration and withdrawal of tetrahydrocannabinols (delta-8-THC and delta-9-THC) on open-field behavior in rats. Pharmacol Biochem Behav 1:243-249.